Open Nav

Amygdala Neurosciences, Inc.

  • Peter Strumph, Amygdala Neurosciences, Inc.

Investor Awarensss

  • Date:Wednesday, October 17
  • Time:10:30 AM - 10:45 AM
  • Room:Elizabethan C
  • Location:2nd Floor
  • Session Type:Company Presentation
  • Presentation Type:Privately Funded Company
  • Company Description/Mission Statement:Amygdala Neurosciences is developing ANS-6637 for the treatment of substance use disorder. NIH funded Phase-2 studies for opioid and alcohol use disorders will begin in 2019. We are also planning to start a Phase-2 study for smoking cessation and studies to support cocaine use disorder development in 2019. ANS-6637 is a novel Phase-2 ready, selective and reversible ALDH2 inhibitor, a new chemical entity with a novel MOA for treating substance use disorder. Based on a mechanism of action in the brain (published in Nature Medicine) that prevents pathophysiologic dopamine surge without changes to basal dopamine, ANS-6637 has the potential to prevent drug seeking behavior, craving and relapse.
  • Company
  • Company HQ City:San Francisco
  • Company HQ Country:United States
  • Company HQ State:California                  
  • Main Therapeutic Focus:CNS/Neurological
  • Lead Product in Development :ANS-6637
  • Development Phase of Primary Product:Phase I
  • Total Amount Raised to Date, In All Rounds:$6 million
Peter Strumph
Amygdala Neurosciences, Inc.